Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
SCION: SABR and Checkpoint Inhibition of NSCLC
- Status
- WITHDRAWN
- Phase
- PHASE2
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE2
SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Lung Cancer With Copanlisib and Durvalumab
- Status
- COMPLETED
- Phase
- PHASE1
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- NA
TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
- Status
- TERMINATED
- Phase
- PHASE2